Seikagaku reported FY3Q21 orthopedic sales of ¥3,555 million ($34.1 million), +4.1% vs. FY3Q20.
The market recovery in Japan and abroad has helped the company increase sales volume. In Japan, Seikagaku is still contending with drug price reductions and the adverse side effects caused by its new JOYCLU knee osteoarthritis treatment.
The company drove impressive growth in its international markets. Gel-One sales in the U.S. increased due to market share gains, stocking orders and the continuing shift toward single-injection treatments. Marketing efforts and stocking orders drove sharp growth of the ARTZ product in China.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
3Q21
3Q20
$ Chg
% Chg
Orthobiologics
$34.1
$32.8
$1.4
4.1%
9mo21
9mo20
$ Chg
% Chg
Orthobiologics
$109.6
$92.9
$16.7
18%
Orthopedic Sales by Geography
3Q21
3Q20
$ Chg
% Chg
Domestic (Japan)
$10.9
$15.4
($4.5)
(29.1%)
International
$23.2
$17.4
$5.8
33.5%
Total
$34.1
$32.8
$1.4
4.1%
9mo21
9mo20
$ Chg
% Chg
Domestic (Japan)
$41.2
$44.3
($3.2)
(7.1%)
International
$68.5
$48.6
$19.8
40.8%
Total
$109.6
$92.9
$16.7
18%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY3Q21 orthopedic sales of ¥3,555 million ($34.1 million), +4.1% vs. FY3Q20.
The market recovery in Japan and abroad has helped the company increase sales volume. In Japan, Seikagaku is still contending with drug price reductions and the adverse side effects caused by its new JOYCLU knee osteoarthritis treatment.
The...
Seikagaku reported FY3Q21 orthopedic sales of ¥3,555 million ($34.1 million), +4.1% vs. FY3Q20.
The market recovery in Japan and abroad has helped the company increase sales volume. In Japan, Seikagaku is still contending with drug price reductions and the adverse side effects caused by its new JOYCLU knee osteoarthritis treatment.
The company drove impressive growth in its international markets. Gel-One sales in the U.S. increased due to market share gains, stocking orders and the continuing shift toward single-injection treatments. Marketing efforts and stocking orders drove sharp growth of the ARTZ product in China.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
3Q21
3Q20
$ Chg
% Chg
Orthobiologics
$34.1
$32.8
$1.4
4.1%
9mo21
9mo20
$ Chg
% Chg
Orthobiologics
$109.6
$92.9
$16.7
18%
Orthopedic Sales by Geography
3Q21
3Q20
$ Chg
% Chg
Domestic (Japan)
$10.9
$15.4
($4.5)
(29.1%)
International
$23.2
$17.4
$5.8
33.5%
Total
$34.1
$32.8
$1.4
4.1%
9mo21
9mo20
$ Chg
% Chg
Domestic (Japan)
$41.2
$44.3
($3.2)
(7.1%)
International
$68.5
$48.6
$19.8
40.8%
Total
$109.6
$92.9
$16.7
18%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
